The Latest Cardiac and Vascular News
SANTA CRUZ, Calif., May 9, 2023 /PRNewswire/ — Emboline, Inc., a privately held medical technology company focused on reducing stroke during structural heart procedures such as transcatheter aortic valve replacement (TAVR), today announced the first patient has been treated in the Protect the Head to Head investigational device exemption (IDE) clinical trial […]
– Children in the ELPIS I trial had 100% survival up to 5 years of age after receiving Lomecel-BTM compared to 20% mortality rate observed from historical control data – – Data reinforce potential survival benefit of Lomecel-BTM for patients with hypoplastic left heart syndrome (HLHS) – – Enrollment ongoing in Phase 2a […]
FDA approval means patients with heart failure can benefit from FARXIGA regardless of left ventricular ejection fraction status WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca’s FARXIGA (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalization for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF. The […]
First clinical gene therapy program for PKP2-ACM, a devastating inherited heart disease affecting approximately 50,000 people in the U.S. and EU Robust preclinical proof of concept studies showed RP-A601 decreased arrhythmias and increased survival in the PKP2 knockout mouse model Initiating Phase 1 trial start-up activities and rapidly working towards first […]
LOS ANGELES, May 7, 2023 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration (SVD) in bioprosthetic aortic valves with the company’s innovative RESILIA tissue. The data, which represent the longest clinical follow-up for Edwards’ bioprosthetic surgical aortic valve with RESILIA […]
RBT-1 achieved the primary biomarker endpoint, as well as several key clinical outcome endpoints; positive data supports the potential for RBT-1 to improve postoperative outcomes in cardiothoracic surgery– RBT-1 as a preconditioning agent has the potential to provide patient benefits in multiple surgical settings where organ injury during surgery increases […]
AUSTIN, Texas and ST. LOUIS, May 8, 2023 /PRNewswire/ — Ucardia, a cardiac conditioning software developer, announced today that it has reached an agreement to acquire Phas3, a pioneer in home-based cardiac rehab and fellow industry leader. This acquisition will result in a comprehensive, market-leading solution for providers, payers, and consumers, covering all facets […]
This research-use-only offering supports the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases. CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a precision cardiovascular medicine company, today announced the availability of its CardioInnovate360TM research-use-only (RUO) solution for biopharmaceutical companies that have and/or are developing therapeutics for […]
Leading experts to shape the future of Viz.ai’s HCM strategy and platform SAN FRANCISCO–(BUSINESS WIRE)–Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the creation of its Hypertrophic Cardiomyopathy (HCM) Medical Advisory Board to assist the company in the development of strategy and products to support […]
NORRISTOWN, Pa.–(BUSINESS WIRE)–Thubrikar Aortic Valve, Inc., is happy to announce that results of the initial CE Mark-enabling study using the Optimum Transcatheter Aortic Valve (Optimum TAV™) in patients with severe aortic stenosis will be presented at the upcoming EuroPCR 2023 Conference. EuroPCR is an annual, world-leading conference on interventional cardiovascular […]
